Literature Search Skill
Search and analyze scientific literature for drug discovery insights.
Quick Start
/pubmed EGFR resistance
/literature-search "KRAS G12C" --year 2023-2024
Find recent papers on PROTAC technology
What are the key publications on ADC toxicity?
What's Included
| Feature |
Description |
| Smart Search |
Automatic query optimization and expansion |
| Summarization |
Key findings extraction from abstracts |
| Trend Analysis |
Publication trends over time, hot topics |
| Key Papers |
High-impact identification by citations |
| Preprints |
bioRxiv/arXiv integration for early access |
| Related Work |
Citation network exploration |
Data Sources
| Source |
Coverage |
API |
| PubMed |
35M+ citations |
E-utilities |
| PubMed Central |
9M+ full-text |
E-utilities |
| bioRxiv |
200K+ preprints |
API |
| medRxiv |
80K+ preprints |
API |
| arXiv |
2M+ preprints |
API |
Output Structure
# Literature Search: EGFR Resistance
## Summary
Found **847 papers** (2020-2024). Key trends: 3rd-gen TKI resistance mechanisms,
C797S mutation targeting, combination strategies, and 4th-generation TKIs.
## Publication Trend
2020: 127 papers
2021: 156 papers ↑23%
2022: 183 papers ↑17%
2023: 198 papers ↑8%
2024 (YTD): 183 papers
**Growth Rate**: +13% CAGR
**Hot Topic Alert**: C797S mutation papers up 340% (2022-2024)
## Key Papers (Top 10)
### 1. Osimertinib resistance mechanisms (Nature Medicine, 2023)
- **Citation**: 234
- **Journal Impact Factor**: 82.9
- **Key Finding**: C797S mutation accounts for 40% of 3rd-gen resistance;
MET amplification 35%, HER2 amplification 15%
- **Authors**: Wang et al. (Memorial Sloan Kettering)
### 2. Fourth-generation EGFR TKIs (Cancer Cell, 2024)
- **Citation**: 89
- **Key Finding**: BLU-945 shows activity against C797S in xenograft models;
clinical data promising
[... 8 more key papers ...]
## Research Themes
### Theme 1: Resistance Mechanisms (45% of papers)
| Sub-theme | Paper Count | Growth |
|-----------|-------------|--------|
| C797S mutation | 127 | +340% |
| MET amplification | 98 | +180% |
| Phenotypic transformation | 67 | +120% |
### Theme 2: Combination Strategies (25% of papers)
| Combination | Evidence Level |
|-------------|----------------|
| EGFR + MET TKI | Phase III positive |
| EGFR + Chemotherapy | Standard of care |
| EGFR + Anti-angiogenic | Mixed results |
### Theme 3: Novel Modalities (15% of papers)
| Modality | Paper Count | Status |
|----------|-------------|--------|
| 4th-gen TKI | 43 | 5 in clinic |
| Bispecific antibodies | 28 | 3 in clinic |
| ADC approaches | 34 | Early |
| PROTAC | 19 | Preclinical |
### Theme 4: Biomarker Discovery (10% of papers)
- ctDNA monitoring
- Early detection of resistance
- Patient stratification
### Theme 5: CNS Metastases (5% of papers)
- Brain penetration strategies
- Intracranial efficacy
## Top Journals
| Journal | Papers | % | Avg IF |
|---------|--------|---|--------|
| Clinical Cancer Research | 78 | 9% | 10.2 |
| J Thorac Oncol | 67 | 8% | 20.1 |
| Nat Commun | 54 | 6% | 16.6 |
| Ann Oncol | 45 | 5% | 50.5 |
## Leading Institutions
| Institution | Papers | Key Collaborators |
|-------------|--------|-------------------|
| Memorial Sloan Kettering | 67 | Dana-Farber, Mass General |
| Dana-Farber Cancer Institute | 54 | MSK, MD Anderson |
| MD Anderson | 48 | DFCI, MSK |
| AstraZeneca | 43 | Academic partners |
## Key Clinical Trials Referenced
| Trial | Phase | Finding | Citation |
|-------|-------|---------|----------|
| FLAURA2 | III | Chemo combo superior | 234 papers |
| MARIPOSA | III | Lazertinib vs osimertinib | 156 papers |
| SAVANNAH | II | MET combo resistance | 89 papers |
## Emerging Keywords (2023-2024)
| Keyword | Frequency | Growth |
|---------|-----------|--------|
| C797S | 234 | +450% |
| Fourth-generation | 189 | +380% |
| Bispecific | 156 | +220% |
| Neoantigen | 98 | +180% |
| Liquid biopsy | 87 | +150% |
## Knowledge Gaps Identified
1. Long-term resistance beyond C797S
2. Optimal combination sequencing
3. Biomarkers for patient selection
4. Quality of life endpoints
Examples
Basic Search
/pubmed EGFR resistance
/literature KRAS inhibitors
Search for ADC toxicity papers
Time-Bounded Search
/pubmed "KRAS G12C" --year 2023-2024
/literature PROTAC --since 2022-06
Papers from last 6 months on GLP-1
Focused Search
/pubmed EGFR --focus clinical
/literature "bispecific antibodies" --focus preclinical
Search reviews only on CAR-T toxicity
Comparison Search
Compare literature on 1st vs 2nd gen EGFR TKIs
/pubmem KRAS vs NRAS vs HRAS clinical data
Trend Analysis
What are the emerging trends in ADC research?
/literature trends obesity drugs --last 5years
Search Operators
| Operator |
Usage |
Example |
AND |
Combine terms |
EGFR AND resistance |
OR |
Either term |
TKI OR antibody |
NOT |
Exclude |
EGFR NOT lung |
* |
Wildcard |
resist* |
"" |
Phrase |
"C797S mutation" |
[] |
MeSH terms |
EGFR[MeSH] |
Running Scripts
# Basic search
python scripts/pubmed_search.py "EGFR resistance" --output results.json
# With date range
python scripts/pubmed_search.py "KRAS G12C" --start 2023-01-01 --end 2024-12-31
# Include full-text
python scripts/pubmed_search.py "PROTAC" --full-text --max 50
# Trend analysis
python scripts/pubmed_search.py "ADC toxicity" --trend --years 5
# Preprints only
python/scripts/pubmed_search.py "mRNA vaccines" --preprints
Requirements
pip install requests pandas biopython
Additional Resources
- PubMed E-utilities API
- Search Strategy Guide
- Data Extraction Scripts
Best Practices
- Start broad, then narrow: Search broad terms first
- Use quotes for phrases:
"C797S mutation" not C797S mutation
- Check recent first: Sort by publication date for current research
- Review high-impact: Check citation count for key papers
- Include preprints: For cutting-edge developments
Common Pitfalls
| Pitfall |
Solution |
| Too many results |
Add specific terms, date range |
| Too few results |
Use synonyms, expand search |
| Missing recent |
Check preprint servers |
| Not specific enough |
Use MeSH terms |
| Overlap |
Remove duplicates before analysis |
Output Options
| Format |
Description |
| Summary (default) |
Key insights, trends, top papers |
| Full |
All papers with abstracts |
| BibTeX |
Citation export |
| CSV |
Data analysis ready |
| Markdown |
Report format |